Skip to main content
. Author manuscript; available in PMC: 2018 Nov 6.
Published in final edited form as: Angew Chem Int Ed Engl. 2017 Oct 5;56(45):14075–14079. doi: 10.1002/anie.201707598

Figure 6.

Figure 6

Antibacterial activity of Vanc-RBC. a) Fluorescence recovery of donor dye after incubation of FRET pair-doped RBC vesicles with MRSA (n = 6; mean ± SD; linear regression). b) Bacteria count after incubation with free Vanc, RBC vesicles, or Vanc-RBC (n = 3; mean ± SD). c) Skin lesion size on mice challenged with MRSA and treated with free Vanc or Vanc-RBC (n = 6; mean ± SEM). *** p < 0.001 (compared to Vanc-RBC); Student’s t-test. d) Enumeration of bacteria in the skin tissue on day 5 (n = 6; geometric mean ± SD). *** p < 0.001, **** p < 0.0001 (compared to Vanc-RBC); Student’s t-test. e) Representative macroscopic images of bacterial challenge site on day 5. f) Representative H&E-stained histological sections of skin from the challenge site on day 5 (scale bar = 200 µm).